Ropidoxuridine for Glioblastoma

Phase 2

Recruiting

Research Sponsored by Shuttle Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up measured from the time of study enrollment until 28 (±7) days following the completion of study treatment.

Awards & highlights

No Placebo-Only Group

Summary

"This trial is testing a drug called ropidoxuridine to see if it can make radiation therapy more effective in patients with a specific type of brain cancer. The study will look at how safe and

Who is the study for?

This trial is for adults with a new diagnosis of IDH-wildtype glioblastoma, which is an aggressive brain cancer, and their tumors must have an unmethylated MGMT promoter. Participants should be ready to undergo standard radiotherapy.

What is being tested?

The study tests ropidoxuridine's effectiveness in making tumor cells more sensitive to radiation therapy. It's a phase 2 trial where patients receive either the usual treatment or the same plus oral ropidoxuridine.

What are the potential side effects?

Ropidoxuridine may increase sensitivity to radiation, potentially leading to enhanced side effects from radiotherapy such as fatigue, skin irritation at the treatment site, headaches, nausea, and hair loss.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ measured from the time of study enrollment until 28 (±7) days following the completion of study treatment.

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~measured from the time of study enrollment until 28 (±7) days following the completion of study treatment.

This trial's timeline: 3 weeks for screening, Varies for treatment, and measured from the time of study enrollment until 28 (±7) days following the completion of study treatment. for reporting.